Naja naja atra Venom Protects against Manifestations of Systemic Lupus Erythematosus in MRL/lpr Mice

• Published in: Evidence-based complementary and alternative medicine Vol. 2014; no. 2014; pp. 1 - 11
• Main Authors: Qin, Zheng-Hong, Ding, Zhi-Hui, Xu, Yin-Li, Wang, Shu-Zhi, Kou, Jian-Qun, Cui, Kui, Zhu, Jia-Li, Han, Rong
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2014; Hindawi Limited
• Subjects: Anti-DNA antibodies; Anxiety; Arthritis; Autoimmune diseases; Bone marrow; Creatine; Creatine kinase; Cytokines; Disease; Drug dosages; Enzyme-linked immunosorbent assay; Erythema; Experiments; Globulins; Inflammation; Inspection; Interleukin 6; Kidneys; Laboratory animals; Liver; Lupus; Lymphadenopathy; Mice; Naja naja; Neurosciences; Open-field behavior; Oral administration; Pathology; Proteinuria; Pyruvic acid; Rheumatic diseases; Rodents; Skin; Spleen; Systemic lupus erythematosus; Transaminase; Tumor necrosis factor; Tumor necrosis factor-TNF; Venom; China
• ISSN: 1741-427X; 1741-4288
• DOI: 10.1155/2014/969482

Systemic lupus erythematosus (SLE) is an autoimmune disease and effective therapy for this pathology is currently unavailable. We previously reported that oral administration of Naja naja atra venom (NNAV) had anti-inflammatory and immune regulatory actions. We speculated that NNAV may have therapeutic effects in MRL/lpr SLE mice. Twelve-week-old MRL/lpr mice received oral administration of NNAV (20, 40, and 80 μg/kg) or Tripterygium wilfordii polyglycosidium (10 mg/kg) daily for 16 weeks. The effects of NNAV on SLE manifestations, including skin erythema, proteinuria, and anxiety-like behaviors, were assessed with visual inspection and Multistix 8 SG strips and open field test, respectively. The pathology of spleen and kidney was examined with H&E staining. The changes in autoimmune antibodies and cytokines were determined with ELISA kits. The results showed that NNAV protected against the manifestation of SLE, including skin erythema and proteinuria. In addition, although no apparent histological change was found in liver and heart in MRL/lpr SLE mice, NNAV reduced the levels of glutamate pyruvate transaminase and creatine kinase. Furthermore, NNAV increased serum C3 and reduced concentrations of circulating globulin, anti-dsDNA antibody, and inflammatory cytokines IL-6 and TNF- α . NNAV also reduced lymphadenopathy and renal injury. These results suggest that NNAV may have therapeutic values in the treatment of SLE by inhibiting autoimmune responses.